Paper32808554
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Jordan AL and 4 others. Mult Scler, 2022. Cited by 61 papers, by iCite.
Cite this record
ConductScience Library. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients. Papers, record 32808554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32808554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukoencephalopathy, Progressive Multifocal | Major topic |
| Lymphopenia | Major topic |
| Multiple Sclerosis | Major topic |
| Aged | |
| Dimethyl Fumarate | |
| Humans | |
| Immunosuppressive Agents |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| UM1 AI110557 | NIAID NIH HHS | United States | UM1AI110557 | PubMed and NIH | NIH RePORTER |
| UM1 AI144298 | NIAID NIH HHS | United States | UM1AI144298 | PubMed and NIH | NIH RePORTER |
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26843383 | Reassessing the risk of natalizumab-associated PML. | J Neurovirol | 2016 | https://conductscience.org/library/papers/26843383 | PubMed |
| 2 | 31675639 | Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis. | Mult Scler Relat Disord | 2020 | https://conductscience.org/library/papers/31675639 | PubMed |
| 3 | 21131916 | Progressive multifocal leukoencephalopathy and other forms of JC virus disease. | Nat Rev Neurol | 2010 | https://conductscience.org/library/papers/21131916 | PubMed |
| 4 | 27606353 | Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. | Neurol Neuroimmunol Neuroinflamm | 2016 | https://conductscience.org/library/papers/27606353 | PubMed |
| 5 | 25920452 | Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. | Acta Neuropathol | 2015 | https://conductscience.org/library/papers/25920452 | PubMed |
| 6 | 27343070 | PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter? | Neurology | 2016 | https://conductscience.org/library/papers/27343070 | PubMed |
| 7 | 1310438 | Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. | Clin Microbiol Rev | 1992 | https://conductscience.org/library/papers/1310438 | PubMed |
| 8 | 28480794 | Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count. | Mult Scler | 2018 | https://conductscience.org/library/papers/28480794 | PubMed |
| 9 | 28989935 | Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment. | J Investig Med High Impact Case Rep | 2017 | https://conductscience.org/library/papers/28989935 | PubMed |
| 10 | 29774781 | Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. | Mult Scler | 2018 | https://conductscience.org/library/papers/29774781 | PubMed |
| 11 | 22733812 | Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. | J Biol Chem | 2012 | https://conductscience.org/library/papers/22733812 | PubMed |
| 12 | 25738172 | Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. | Neurol Neuroimmunol Neuroinflamm | 2015 | https://conductscience.org/library/papers/25738172 | PubMed |
| 13 | 20664170 | Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20664170 | PubMed |
| 14 | 28958667 | Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. | J Autoimmun | 2018 | https://conductscience.org/library/papers/28958667 | PubMed |
| 15 | 8748293 | Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. | J Clin Microbiol | 1996 | https://conductscience.org/library/papers/8748293 | PubMed |
| 16 | 24691444 | Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. | J Clin Invest | 2014 | https://conductscience.org/library/papers/24691444 | PubMed |
| 17 | 29456537 | Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View. | Front Immunol | 2018 | https://conductscience.org/library/papers/29456537 | PubMed |
| 18 | 28491903 | Dimethyl fumarate alters B-cell memory and cytokine production in MS patients. | Ann Clin Transl Neurol | 2017 | https://conductscience.org/library/papers/28491903 | PubMed |
| 19 | 9168952 | Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. | Biochem Biophys Res Commun | 1997 | https://conductscience.org/library/papers/9168952 | PubMed |
| 20 | 22992073 | Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22992073 | PubMed |
Cited by43
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42907929 | Proportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis. | Neurol Res Pract | 2026 | https://conductscience.org/library/papers/42907929 | PubMed |
| 42168998 | Viral associations in multiple sclerosis: pathogenetic mechanisms and therapeutic implications. | Virol J | 2026 | https://conductscience.org/library/papers/42168998 | PubMed |
| 41627610 | Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/41627610 | PubMed |
| 41486342 | Mitochondria as a therapeutic target in neurodegeneration caused by hypoxia and ischemia during the perinatal period. | Pharmacol Rep | 2026 | https://conductscience.org/library/papers/41486342 | PubMed |
| 41316372 | Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis. | J Neuroinflammation | 2025 | https://conductscience.org/library/papers/41316372 | PubMed |
| 41116174 | Dimethyl fumarate reprograms cervical cancer cells to enhance antitumor immunity by activating mtDNA-cGAS-STING pathway. | J Biomed Sci | 2025 | https://conductscience.org/library/papers/41116174 | PubMed |
| 41034190 | Multiple sclerosis: molecular pathogenesis and therapeutic intervention. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/41034190 | PubMed |
| 40832152 | JCV-specific cell-based assays for PML risk assessment in lupus and multiple sclerosis patients with and without natalizumab. | Front Neurol | 2025 | https://conductscience.org/library/papers/40832152 | PubMed |
| 40715945 | JC Polyomavirus Infection: A Narrative Review. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/40715945 | PubMed |
| 40649894 | Repurposing Dimethyl Fumarate Targeting Nrf2 to Slow Down the Growth of Areas of Geographic Atrophy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40649894 | PubMed |
| 40465056 | A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS). | J Neurol | 2025 | https://conductscience.org/library/papers/40465056 | PubMed |
| 40221354 | Choosing initial MS therapy; personal, disease, and medication factors. | Neurotherapeutics | 2025 | https://conductscience.org/library/papers/40221354 | PubMed |
| 39890857 | Dimethyl fumarate effects on paraquat-induced hepatotoxicity in mice via anti-oxidative, anti-inflammatory, and anti-apoptotic activities. | Sci Rep | 2025 | https://conductscience.org/library/papers/39890857 | PubMed |
| 39767644 | Analysis of Immunological Memory for John Cunningham Virus in a Mexican Population of Patients with Multiple Sclerosis Under Treatment. | Biomedicines | 2024 | https://conductscience.org/library/papers/39767644 | PubMed |
| 39707906 | De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. | Brain | 2025 | https://conductscience.org/library/papers/39707906 | PubMed |
| 39466585 | Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study. | Clin Drug Investig | 2024 | https://conductscience.org/library/papers/39466585 | PubMed |
| 39287981 | Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis. | J Clin Invest | 2024 | https://conductscience.org/library/papers/39287981 | PubMed |
| 39200354 | Understanding the Complex Dynamics of Immunosenescence in Multiple Sclerosis: From Pathogenesis to Treatment. | Biomedicines | 2024 | https://conductscience.org/library/papers/39200354 | PubMed |
| 38999279 | Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest. | J Clin Med | 2024 | https://conductscience.org/library/papers/38999279 | PubMed |
| 38960947 | Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report. | J Neurol | 2024 | https://conductscience.org/library/papers/38960947 | PubMed |
Genes25
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32808554
GET https://conductscience.org/api/papers/v1/32808554/references?page=2